---
title: "Corbus appoints Brent Pfeiffenberger to board with equity awards"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287219532.md"
description: "Corbus has appointed Brent Pfeiffenberger to its board, effective May 19, 2026, granting him stock options for 24,700 shares and 7,500 restricted stock units. Both awards will vest in three equal annual installments, contingent on continued service."
datetime: "2026-05-21T12:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287219532.md)
  - [en](https://longbridge.com/en/news/287219532.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287219532.md)
---

# Corbus appoints Brent Pfeiffenberger to board with equity awards

**Corbus appointed Brent Pfeiffenberger to its board and granted him stock option and restricted stock unit awards effective May 19, 2026.**

Individual

Brent Pfeiffenberger

Role

Appointed to the Board

Type of Change

Appointed

Effective Date

May 19, 2026

Reason

In connection with appointment to the Board

Replacement Info

Not disclosed

Background Details

Granted nonqualified option for 24,700 shares (10-year term to May 19, 2036) and 7,500 RSUs; both vest in three equal annual installments subject to continued service

Board/Committee Role Changes

Not disclosed

Original SEC Filing: Corbus Pharmaceuticals Holdings, Inc. \[ CRBP \] - 8-K - May. 21, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)

## Related News & Research

- [Brokers Offer Predictions for CRBP Q2 Earnings](https://longbridge.com/en/news/286408539.md)
- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/286342985.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Cor appoints Brent Pfeiffenberger to board as independent director](https://longbridge.com/en/news/286416248.md)